News

Patients with Acute Myeloid Leukemia (AML) have very few treatment options when the initial chemotherapy has failed. This is particularly true for patients over 60, or with co-morbidities, who are not eligible for stem cell transplantation. On average, they will survive only a few months.

The results of the AML-ViVA trial show that low dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients who do not respond to initial chemotherapy.

A Cambridge-led trial testing a potential new treatment combination for post-menopausal women with hormone driven breast cancer reports positive findings at the international San Antonio Breast Cancer Symposium.

The results show that either a high or low dose of megestrol when given with the standard hormone therapy, letrozole, could be more effective in stopping tumour growth than letrozole alone.

The Anticancer Fund aims to intensify its commitment to helping patients confronted with pancreatic cancer and finding solutions for treatment. As November marks Pancreatic Cancer Awareness Month, we underscore the urgent need for dedicated research during a meeting of the European REMEDi4ALL consortium.

The Anticancer Fund, a non-profit organisation dedicated to advancing cancer research and treatment, is proud to announce its active participation in the annual Connective Tissue Oncology Society (CTOS) meeting, taking place in Dublin, Ireland. Two of the clinical trials we support, will present their findings at the conference.

The Anticancer Fund (ACF) and the International Society of Geriatric Oncology (SIOG) are collaborating to present an interactive webinar focused on enhancing cancer care for older adults: Shared decision-making in Geriatric Oncology.

In the face of adversity, Gilles van der Spek, a 35-year old diagnosed with incurable cancer, has shown resilience and determination. He started raising funds for the Anticancer Fund and in doing so, embarked on a journey that captured hearts globally.